肝癌患者-话题@MedSci

#肝癌患者#

80篇内容 | 2247人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1968999, encodeId=f73b1968999cf, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JAMA Surg：肝癌患者肝切除术后与肝功能失代偿相关危险因素研究, objectType=article, longId=80360, objectId=83c980360e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83c980360e8, replyNumber=0, likeNumber=74, createdTime=2017-05-09, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83c980360e8, moduleTitle=JAMA Surg：肝癌患者肝切除术后与肝功能失代偿相关危险因素研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83c980360e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969006, encodeId=ceb71969006f8, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益, objectType=article, longId=103381, objectId=15e41033812f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e41033812f, replyNumber=0, likeNumber=85, createdTime=2017-07-26, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e41033812f, moduleTitle=秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e41033812f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969004, encodeId=4cbe19690045a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Clin Gastroenterol H：雌激素替代疗法降低女性肝癌患者的风险和增加生存时间！, objectType=article, longId=100693, objectId=121e1006930e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121e1006930e, replyNumber=0, likeNumber=104, createdTime=2017-12-20, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121e1006930e, moduleTitle=Clin Gastroenterol H：雌激素替代疗法降低女性肝癌患者的风险和增加生存时间！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121e1006930e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969001, encodeId=a3491969001d3, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Lancet:：索拉非尼治疗的肝癌患者疾病进展后用瑞戈非尼治疗有效吗？, objectType=article, longId=83644, objectId=8fd9836447e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fd9836447e, replyNumber=0, likeNumber=96, createdTime=2017-03-19, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fd9836447e, moduleTitle=Lancet:：索拉非尼治疗的肝癌患者疾病进展后用瑞戈非尼治疗有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fd9836447e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969002, encodeId=735c196900228, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=HEPATOLOGY：上海药物所揭示 pIgR/p-Yes 亚群分型是肝癌患者生存的预后标志物, objectType=article, longId=94233, objectId=67f19423360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67f19423360, replyNumber=0, likeNumber=69, createdTime=2018-03-04, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67f19423360, moduleTitle=HEPATOLOGY：上海药物所揭示 pIgR/p-Yes 亚群分型是肝癌患者生存的预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67f19423360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968998, encodeId=f039196899865, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JAMA子刊：不产生AFP的肝癌患者，肝移植后复发率和生存率如何？, objectType=article, longId=79684, objectId=e6a7e968469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6a7e968469, replyNumber=0, likeNumber=63, createdTime=2017-01-26, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6a7e968469, moduleTitle=JAMA子刊：不产生AFP的肝癌患者，肝移植后复发率和生存率如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6a7e968469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968996, encodeId=9ee619689962e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, objectType=article, longId=71847, objectId=9b2ae184708, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b2ae184708, replyNumber=0, likeNumber=66, createdTime=2016-09-26, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b2ae184708, moduleTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b2ae184708)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968995, encodeId=9b8a1968995d3, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：晚期肝癌患者需警惕门静脉高压, objectType=article, longId=58143, objectId=85be581432f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85be581432f, replyNumber=0, likeNumber=82, createdTime=2016-08-30, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85be581432f, moduleTitle=Hepatology：晚期肝癌患者需警惕门静脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85be581432f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968997, encodeId=399c196899eba, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？, objectType=article, longId=76072, objectId=b031e607267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b031e607267, replyNumber=0, likeNumber=161, createdTime=2016-09-08, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b031e607267, moduleTitle=J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b031e607267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968994, encodeId=e3c719689948e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率, objectType=article, longId=52347, objectId=18bb5234e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18bb5234e82, replyNumber=0, likeNumber=53, createdTime=2015-09-13, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18bb5234e82, moduleTitle=Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18bb5234e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968989, encodeId=3fe91968989e7, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=ASCO 2014：阿帕替尼治疗中国进展期肝癌患者的II期研究, objectType=article, longId=35647, objectId=fc533564e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc533564e61, replyNumber=0, likeNumber=71, createdTime=2014-10-25, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc533564e61, moduleTitle=ASCO 2014：阿帕替尼治疗中国进展期肝癌患者的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc533564e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968990, encodeId=c7e119689900a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验, objectType=article, longId=35648, objectId=35c7356487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c7356487a, replyNumber=0, likeNumber=68, createdTime=2014-09-22, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c7356487a, moduleTitle=ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c7356487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968992, encodeId=193e19689929d, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JAMA：药物依维莫司在晚期肝癌患者中不能提高总体存活率, objectType=article, longId=37471, objectId=3d7d3e47160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7d3e47160, replyNumber=0, likeNumber=81, createdTime=2015-03-21, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7d3e47160, moduleTitle=JAMA：药物依维莫司在晚期肝癌患者中不能提高总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7d3e47160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968988, encodeId=a341196898800, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=EASL 2014：肝癌患者生存率与筛查强度相关, objectType=article, longId=33351, objectId=296c33351a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=296c33351a2, replyNumber=0, likeNumber=64, createdTime=2014-12-29, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=296c33351a2, moduleTitle=EASL 2014：肝癌患者生存率与筛查强度相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=296c33351a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968991, encodeId=83fd196899158, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JAMA：依维莫司不能提高晚期肝癌患者总体存活率（EVOLVE-1研究）, objectType=article, longId=37382, objectId=50a33e38234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a33e38234, replyNumber=0, likeNumber=60, createdTime=2014-11-22, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a33e38234, moduleTitle=JAMA：依维莫司不能提高晚期肝癌患者总体存活率（EVOLVE-1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50a33e38234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968986, encodeId=3726196898678, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JCO：秦叔逵-FOLFOX4方案或让亚洲肝癌患者获益, objectType=article, longId=23586, objectId=a4d02358610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4d02358610, replyNumber=0, likeNumber=0, createdTime=2014-02-04, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4d02358610, moduleTitle=JCO：秦叔逵-FOLFOX4方案或让亚洲肝癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4d02358610)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968993, encodeId=0ea1196899301, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=J Hepatol：超米兰标准中期多发性肝癌患者肝切除术优于介入治疗, objectType=article, longId=38240, objectId=5af03824048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af03824048, replyNumber=0, likeNumber=72, createdTime=2014-11-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af03824048, moduleTitle=J Hepatol：超米兰标准中期多发性肝癌患者肝切除术优于介入治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af03824048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968987, encodeId=8e48196898ecc, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JCO:布立尼布不能改善肝癌患者生存, objectType=article, longId=23914, objectId=80e52391402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e52391402, replyNumber=0, likeNumber=60, createdTime=2014-03-03, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e52391402, moduleTitle=JCO:布立尼布不能改善肝癌患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e52391402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968985, encodeId=d438196898528, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Jennerex启动JX-594在晚期肝癌患者的II期临床试验, objectType=article, longId=8433, objectId=14d184330d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d184330d, replyNumber=0, likeNumber=77, createdTime=2012-11-21, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d184330d, moduleTitle=Jennerex启动JX-594在晚期肝癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14d184330d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968984, encodeId=f35e1968984e1, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=放疗如何使肝癌患者获益？, objectType=article, longId=4029, objectId=e25640291e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e25640291e, replyNumber=0, likeNumber=54, createdTime=2012-03-11, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e25640291e, moduleTitle=放疗如何使肝癌患者获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e25640291e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝癌患者

2020-05-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JAMA Surg：肝癌患者肝切除术后与肝功能失代偿相关危险因素研究

2017-05-09

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益

2017-07-26

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Clin Gastroenterol H：雌激素替代疗法降低女性肝癌患者的风险和增加生存时间！

2017-12-20

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Lancet:：索拉非尼治疗的肝癌患者疾病进展后用瑞戈非尼治疗有效吗？

2017-03-19

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

HEPATOLOGY：上海药物所揭示 pIgR/p-Yes 亚群分型是肝癌患者生存的预后标志物

2018-03-04

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JAMA子刊：不产生AFP的肝癌患者，肝移植后复发率和生存率如何？

2017-01-26

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功

2016-09-26

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：晚期肝癌患者需警惕门静脉高压

2016-08-30

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？

2016-09-08

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率

2015-09-13

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

ASCO 2014：阿帕替尼治疗中国进展期肝癌患者的II期研究

2014-10-25

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验

2014-09-22

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JAMA：药物依维莫司在晚期肝癌患者中不能提高总体存活率

2015-03-21

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

EASL 2014：肝癌患者生存率与筛查强度相关

2014-12-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JAMA：依维莫司不能提高晚期肝癌患者总体存活率（EVOLVE-1研究）

2014-11-22

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JCO：秦叔逵-FOLFOX4方案或让亚洲肝癌患者获益

2014-02-04

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

J Hepatol：超米兰标准中期多发性肝癌患者肝切除术优于介入治疗

2014-11-10

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JCO:布立尼布不能改善肝癌患者生存

2014-03-03

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Jennerex启动JX-594在晚期肝癌患者的II期临床试验

2012-11-21

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

放疗如何使肝癌患者获益？

2012-03-11

科室
- - 订阅+
  - 更多科室
工具
服务